A more resilient supply chain for US-marketed pharmaceuticals could result from fast-track Senate legislation to address the coronavirus pandemic and economic fallout.
In the months since the COVID-19 coronavirus outbreak began in December in Wuhan, China, infections and related quarantines and travel bans have delayed and slowed the manufacture of
It remains unclear whether and to what extent the outbreak, now a global pandemic, will disrupt